Sonia Dutta1, Felicia Lane2. 1. Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, 333 City Blvd, West, Suite 1400, Orange, CA 92868, USA. 2. University of California, Irvine Medical Center, Orange, CA, USA.
Abstract
BACKGROUND: Treatment options for refractory recurrent urinary tract infections (UTI) are limited; therefore, we sought to determine if intravesical instillations with heparin effectively treat recurrent UTIs. METHODS: Patients at an academic medical center who received intravesical instillations with heparin for recurrent UTIs/chronic cystitis between January 2011 and December 2015 were identified via International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) procedure codes. All cases were analyzed for frequency of UTIs during the treatment phase as well as for the subsequent 6 months after completion of therapy. Demographic, clinical and treatment related factors were then collected from the medical records to draw associations with success or failure of treatment. RESULTS: Thirty-nine women were treated with heparin intravesical instillations for recurrent UTIs. The average age of the cohort was 68.38 years [range 25-88, standard deviation (SD) 12.92], with mean parity 2.38 (range 0-7, SD 1.55) and mean body mass index 27.85 (range 19.5-37.9, SD 4.84). A total of 84.6% completed the recommended 6-week treatment course while 69.2% went on to an additional maintenance phase. Twelve patients (30.8%) had a culture-proven UTI during the treatment phase. In the 6-month follow-up period, 46.2% of patients had at least one UTI with only seven patients (17.9%) meeting criteria for recurrent UTIs (two or more UTIs in 6 months). On univariable assessment, development of recurrent UTIs after completion of instillation therapy was associated with increasing age and vaginal estrogen use during the instillation treatment course. CONCLUSIONS: Intravesical instillation with heparin is an effective option to consider for the treatment of refractory recurrent UTIs.
BACKGROUND: Treatment options for refractory recurrent urinary tract infections (UTI) are limited; therefore, we sought to determine if intravesical instillations with heparin effectively treat recurrent UTIs. METHODS: Patients at an academic medical center who received intravesical instillations with heparin for recurrent UTIs/chronic cystitis between January 2011 and December 2015 were identified via International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) procedure codes. All cases were analyzed for frequency of UTIs during the treatment phase as well as for the subsequent 6 months after completion of therapy. Demographic, clinical and treatment related factors were then collected from the medical records to draw associations with success or failure of treatment. RESULTS: Thirty-nine women were treated with heparin intravesical instillations for recurrent UTIs. The average age of the cohort was 68.38 years [range 25-88, standard deviation (SD) 12.92], with mean parity 2.38 (range 0-7, SD 1.55) and mean body mass index 27.85 (range 19.5-37.9, SD 4.84). A total of 84.6% completed the recommended 6-week treatment course while 69.2% went on to an additional maintenance phase. Twelve patients (30.8%) had a culture-proven UTI during the treatment phase. In the 6-month follow-up period, 46.2% of patients had at least one UTI with only seven patients (17.9%) meeting criteria for recurrent UTIs (two or more UTIs in 6 months). On univariable assessment, development of recurrent UTIs after completion of instillation therapy was associated with increasing age and vaginal estrogen use during the instillation treatment course. CONCLUSIONS: Intravesical instillation with heparin is an effective option to consider for the treatment of refractory recurrent UTIs.
Authors: Antonio Cicione; Francesco Cantiello; Giuseppe Ucciero; Andrea Salonia; Immacolata Madeo; Ilaria Bava; Antonio Aliberti; Rocco Damiano Journal: Int J Urol Date: 2014-03-19 Impact factor: 3.369
Authors: Antonio Cicione; Francesco Cantiello; Giuseppe Ucciero; Andrea Salonia; Marco Torella; Marco De Sio; Riccardo Autorino; Antonio Carbone; Martin Romancik; Roman Tomaskin; Rocco Damiano Journal: Can Urol Assoc J Date: 2014-09 Impact factor: 1.862
Authors: E Costantini; M Lazzeri; D Pistolesi; M Del Zingaro; E Frumenzio; A Boni; A Pietropaolo; E Fragalà; M Porena Journal: Urol Int Date: 2013-03-13 Impact factor: 2.089
Authors: C Constantinides; T Manousakas; P Nikolopoulos; A Stanitsas; K Haritopoulos; A Giannopoulos Journal: BJU Int Date: 2004-06 Impact factor: 5.588
Authors: Oriana Ciani; Erik Arendsen; Martin Romancik; Richard Lunik; Elisabetta Costantini; Manuel Di Biase; Giuseppe Morgia; Eugenia Fragalà; Tomaskin Roman; Marian Bernat; Giorgio Guazzoni; Rosanna Tarricone; Massimo Lazzeri Journal: BMJ Open Date: 2016-03-31 Impact factor: 2.692